Younger patients with higher vancomycin dosing attained an initial therapeutic trough in 41.1% vs. 32.7%.
Conclusion. A higher initial vancomycin dose trended toward an improved rate of therapeutic troughs in children 1 month to 12 years old. There was no evidence of increase in the rate of AKI or supratherapeutic troughs. While vancomycin dosing remains challenging, a policy permitting higher initial dosing may more adequately treat dangerous infections without risking adverse effects. Further study of higher vancomycin dosing is warranted.
Disclosures. All authors: No reported disclosures. Background. Aerosolized or powdered forms of polymyxin have been used as prophylaxis for ventilator associated infections in adults. In 2015, Children's National Medical Center neonatal intensive care unit (NICU) protocol recommended that neonates <1,000 g receive polymyxin endotracheal tube suction catheter flushes with the goal to reduce acquired respiratory infection. The objective of this study was to describe the clinical characteristics and outcomes of patients who received polymyxin endotracheal tube flushes compared with those who received saline.
Practice of Endotracheal Tube Suction Catheter Flushes With Polymyxin in Extremely Low Birthweight Neonates
Methods. A retrospective cohort study of infants weighing <1,000 g ventilated for >48 hours in the NICU, January 1, 2015-June 30, 2016 was performed. Data were collected from an internal NICU database, medication billing data, and through chart review of the electronic health record. Demographics, antibiotic treatment days, ventilator days, length of stay, mortality, and microbiologic culture data were compared between patients receiving polymyxin and saline using chi-squared for binary and t-test for continuous variables.
Results. Of the 71 patients included, 38 received polymyxin and 33 received saline. Mean gestational age at birth was 24.1 weeks (23.9 polymyxin vs. 24.2 saline, P = 0.06); median age on admission 4 days (3 vs 12, P = 0.019); median admission weight 700 g (640 vs. 800, P = 0.002); 52% were male (58% vs. 45% group). Median antibiotic days was 52 (77 vs. 41, P = 0.056), median ventilator days 39 (43.5 vs. 33, P = 0.06). Pathogenic bacteria was cultured in 38% of patients in whom at least one lower respiratory tract (LRT) culture was obtained (62.5% vs. 38.1% P = 0.24). Pathogenic bacteria resistant to at least one antibiotic class to which is normally susceptible was found in 10% (13% vs. 6%, P = 0.32). No differences were seen in mortality (16% vs. 15%, P = 0.94) or median length of stay (101 vs. 92, P = 0.41).
Conclusion. An NICU protocol recommending prophylactic polymyxin use for ELBW infants was implemented more frequently in younger and more premature neonates. Mortality and length of stay did not differ among babies who received polymyxin. Patients who received polymyxin did not grow a statistically significant higher proportion of pathogenic or resistant bacteria from LRT cultures compared with those receiving saline.
Disclosures. All authors: No reported disclosures. Background. Although multidrug-resistant (MDR) Gram-negative bacilli (GNB) are a serious and growing concern worldwide, the epidemiological data on children are still limited. Our aim was to evaluate the risk factors for MDR GNB bloodstream infections (BSI) in children.
Risk Factors of Multidrug-Resistant Gram-Negative Bacterial Bloodstream Infections in Children's Hospitals in Japan
Methods. Patients with GNB BSI were enrolled between April 2010 and March 2017 at eight children's hospitals in Japan. Clinical and microbiological data were collected retrospectively. The 2012 criteria of the Centers for Disease Control and Prevention were used to define MDR. MDR and non-MDR GNB BSI were then compared in terms of risk factors.
Results. In total, 629 GNB BSI cases were identified. The median age and proportion of males was 2 years (IQR 0.3-8.7) and 50.7%, respectively. Underlying diseases were found in 94% of the patients. The proportion of GNB BSI cases developing after >48 hours from admission was 76.2%. The most common GNB was Escherichia coli (29.3%, 184/629), followed by Klebsiella pneumoniae (19.7%, 124/629) and Pseudomonas aeruginosa (16.4%, 103/629). MDR comprised 24.5% (154/629) of cases. The MDR rate for E. coli, K. pneumoniae, and P. aeruginosa was 44.0% (81/184), 23.4% (29/124), and 16.5% (17/103), respectively. The coverage rate of the initial empiric therapy for the MDR and non-MDR GNB BSI cases was 60.4% and 83.4%, respectively (P < 0.001). The all-cause mortality rate at 28 days of GNB BSI was 10.7% (67/629), 13.6% (21/154), and 9.7% (46/475) for MDR-and non-MDR GNB BSI, respectively (P = 0.167). The all-cause mortality rate at 28 days was 10.4% (14/135) and 7.7% (27/351) for MDR and non-MDR Enterobacteriaceae BSI (P = 0.341) and 41.2% (7/17) and 18.6% (16/86) for MDR-and non-MDR P. aeruginosa BSI, respectively (P = 0.056). Multivariate logistic regression analysis showed that MDR GNB BSI was independently associated with anticarcinogenic drug use within 30 days (OR: 43.90; 95% CI: 4.69-411.08), older age (OR: 1.05; 95% CI: 1.02-1.09), and admission to the neonatology ward (OR 0.019; 95% CI: 0.005-0.076).
Conclusion. One-fourth of GNB BSI cases were MDR. Anticarcinogenic drug use and older age were risk factors for MDR GNB BSI in children's hospitals. MDR P. aeruginosa infections were associated with higher all-cause mortality.
Disclosures. Background. Acinetobacter baumannii has emerged as an important opportunistic pathogen. Its ability to develop resistance to multiple antibiotics leaves few treatment options. AdeRS, a two-component regulatory system, which controls expression of the adeABC efflux pump is involved in multidrug resistance. There is lack of data regarding presence of virulence factors leading to antimicrobial resistance and their correlation with the outcome of the patients. The study was done to evaluate the prevalence of virulence factors AdeRS gene responsible for the accentuation of drug resistance, and correlation with the clinical outcome of the patient.
Methods. Clinical details of 80 patients with labeled A. baumannii infection were collected and analyzed with the resistance patterns of the isolates and molecular detection of the AdeRS virulence gene.
Results. 80 patients with labeled A. baumannii infection were included in the study. Most common presentation among patients with A. baumannii was pneumonia (46.25%) followed by sepsis. 63.75% of patients were admitted in the ICU. Neonates were mostly affected. Of the total 37 neonates with A. baumannii infections, 26 were hospital acquired. Mean weight of neonates with infection was 2.1 kg. 45.9% neonates with A. baumannii infections had undergone surgery for congenital anomalies. Sepsis was the most common presentation among neonates. Overall, mortality was 41.25%. The maximum mortality was among neonates (57.6%). Children presenting with sepsis had a higher mortality. Mortality in ICU patients was 78.8% compared with 21% in the wards. Average length of stay in the hospital after acquisition of A. baumannii infection was 20.2 days. Of the total 80 isolates, 2.5% were MDR and 86.25% were XDR strains. AdeRS was present in 90% of the isolates. All the isolates with XDR pattern of drug resistance had AdeRS gene. 27.5% of the isolates were tigecycline resistant and AdeRS gene was present in all them. Thirty-three patients who died all possessed AdesRS gene and were XDR strains.
Conclusion.
A. baumannii is responsible for a substantial percentage of nosocomial infections. Presence of AdeRS gene reduces the susceptibility to large number of drugs and thus selects out XDR A. baumannii with high mortality rates in the hospital settings, leaving efflux pump inhibitors as the therapy of choice.
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